Evidence map›Paper›PMID 40774287›Full record

ArticleChronic obstructive pulmonary diseases (Miami, Fla.)2025

Low Lung Function in Middle-Aged Smokers Impacts Health Status, Morbidities, and Mortality: An Observational Analysis of the Lovelace Smokers Cohort.

Yohannes Tesfaigzi, Mary N Brown, Congjian Liu, François-Xavier Blé, Darlene Harbour, Steven A Belinsky, Maria A Picchi, Ventzislava A Hristova, Kristoffer Ostridge, Mehul Patel and 2 more

Abstract read
In one paragraph

Article in Chronic obstructive pulmonary diseases (Miami, Fla.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yohannes TesfaigziDivision of Pulmonary and Critical Care Medicine, Mass General Brigham, Harvard Medical School, Boston, Massachusetts, United States.
Mary N BrownEarly Respiratory and Immunology Clinical Development, BioPharmaceuticals R&D, AstraZeneca, Boston, Massachusetts, United States.
Congjian LiuDivision of Pulmonary and Critical Care Medicine, Mass General Brigham, Harvard Medical School, Boston, Massachusetts, United States.
François-Xavier BléTranslational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
Darlene HarbourLovelace Scientific Resources, Albuquerque, New Mexico, United States.
Steven A BelinskyLovelace Biomedical Research Institute, Albuquerque, New Mexico, United States.
Maria A PicchiLovelace Biomedical Research Institute, Albuquerque, New Mexico, United States.
Ventzislava A HristovaDynamic Omics, Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, United States.
Kristoffer OstridgeTranslational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology, AstraZeneca, Gothenburg, Sweden.
Mehul PatelLate Respiratory and Immunology Clinical Development, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
Paul DorinkskyLate Respiratory and Immunology Clinical Development, BioPharmaceuticals R&D, AstraZeneca, Durham, North Carolina, United States.
Bartolome R CelliDivision of Pulmonary and Critical Care Medicine, Mass General Brigham, Harvard Medical School, Boston, Massachusetts, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Pulmonary function tests may predict future outcomes; however, they are not often performed in middle-aged individuals at risk for future airway obstruction. We examined whether smokers with low lung function (LLF) have an increased risk of developing health problems and mortality over time. Methods: Current and ever smokers (n=830) from the Lovelace Cohort aged 40-60 years without baseline airway obstruction and with at least 2 spirometry measurements over 18 months were included. Participants were divided into high lung function (HLF) and LLF function tertiles based on forced expiratory volume in 1 second percentage predicted (FEV Results: Baseline demographic and clinical characteristics were generally similar between the LLF and HLF tertiles, except for age, sex, body mass index, and lung function. In the overall cohort (LLF, n=277; HLF, n=277), survival of the HLF versus LLF cohort showed a hazard ratio of 0.49 ( Conclusions: Smokers with LLF without airflow obstruction exhibited reduced survival and an increased risk for development of chronic morbidities. Thus, spirometry may be used to identify at-risk individuals, allowing for early preventative interventions that can improve long-term health outcomes.

Indexed as

comorbidityhealth statuslung functionmiddle-aged smokersmortality

Identifiers

PMID40774287
PMCPMC12614190

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.